Physician profile
Mark Christopher Jeranko
NPI 1114304573
$6,433.24
in general payments reported to CMS, 2019-2025
23 companies · $1,890 in 2025
The $1,890 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,415 · 2020: $37.85 · 2022: $194 · 2023: $1,448 · 2024: $1,450 · 2025: $1,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,758 · Education: $28.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,758.28 |
| Education | $28.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,274.07 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Ucb, INC. | $730.25 | 2023-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $659.88 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $653.11 | 2023-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $447.46 | 2019-2025 | |
| Horizon Therapeutics Plc | $378.71 | 2023 | Krystexxa |
| Pfizer INC. | $355.28 | 2019-2025 | |
| Lilly USA, LLC | $335.69 | 2023-2025 | Taltz |
| Janssen Biotech, INC. | $312.56 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $236.85 | 2024-2025 | Orencia |
| Glaxosmithkline, LLC. | $182.30 | 2019-2025 | Benlysta |
| Radius Health, INC. | $173.66 | 2019-2025 | Tymlos |
| Janssen Scientific Affairs, LLC | $153.32 | 2022-2025 | Tremfya |
| Celgene Corporation | $132.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $130.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $56.31 | 2024-2025 | Purified Cortrophin Gel |
| Celltrion USA INC. | $51.38 | 2023-2024 | Yuflyma, Vegzelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.12 | 2023-2024 | Cyltezo |
| Genentech USA, INC. | $38.51 | 2023-2024 | Actemra |
| Kiniksa Pharmaceuticals International, Plc | $34.39 | 2024 | Arcalyst |
| Pacira Pharmaceuticals Incorporated | $25.36 | 2023 | Zilretta |
| Scilex Pharmaceuticals INC. | $16.66 | 2024 | |
| Genzyme Corporation | $15.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jeranko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.